GoodRx Named One of the 2024 TIME100 Most Influential Companies
30 Mai 2024 - 2:35PM
Business Wire
GoodRx honored for creating new ways to deliver significant
savings on prescription medications
Today, GoodRx (Nasdaq: GDRX), the leading destination for
prescription savings in the U.S., was named to the fourth-annual
TIME100 Most Influential Companies list, which highlights
companies making an extraordinary impact around the world. This is
the second time GoodRx has received this honor for helping
Americans get the medications they need at a price they can
afford.
“We are thrilled to be recognized for our work to reduce the
cost of prescription medications for consumers, and the impact
we’ve had on creating healthier people and communities," said Scott
Wagner, Interim CEO of GoodRx. "It would be easy to claim that
rising healthcare costs are an insurmountable challenge, but the
reality is that change is possible. Through innovations that can
benefit stakeholders across the healthcare ecosystem, we are
helping realign the industry around a shared goal: helping people
afford and access their prescription medications.”
Over the last year, GoodRx created new ways to get more
affordable prescriptions into the hands of consumers by integrating
GoodRx savings with insurance benefits, contracting directly with
pharmacies to reduce the price of prescriptions, and working with
pharmaceutical manufacturers to expand the accessibility of brand
medications. As a result, the company saved consumers approximately
$15 billion in 2023 alone compared to pharmacy retail price.
The savings created by GoodRx each year can amount to
significant impact over time. Since its founding in 2011, GoodRx
has helped users obtain at least 184 million prescriptions they
otherwise may not have been able to afford, based on internal
estimates. By helping people access and stay on their prescribed
medications, GoodRx has helped save the healthcare system more than
$5 billion in preventable ER visits and hospitalizations, based on
internal estimates.
To assemble the list, TIME solicited nominations across sectors,
and polled its global network of contributors and correspondents,
as well as outside experts. Then TIME editors evaluated each on key
factors, including impact, innovation, ambition, and success. The
result is a diverse group of 100 businesses helping chart an
essential path forward, including GoodRx.
To view the full TIME100 Most Influential Companies list, visit:
time.com/100companies.
About GoodRx
GoodRx is the leading destination for prescription savings in
the U.S. We offer consumers free access to transparent and lower
prices for generic and brand medications, as well as comprehensive
healthcare research and information. We also equip healthcare
professionals with efficient ways to find and prescribe affordable
medications. Since 2011, GoodRx has helped consumers save nearly
$75 billion and is one of the most downloaded medical apps over the
past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding consumer savings; the benefits and value of
our offerings to consumers and other stakeholders in the healthcare
ecosystem, our product initiatives and our plans, expectations and
objectives. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, risks
relating to our ability to achieve broad market education and
change consumer purchasing habits, changes in medication pricing
and pricing structures, our reliance on a limited number of
industry participants, the competitive nature of our industry, and
the important factors discussed in the section entitled “Risk
Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2023, and our other filings with the SEC. These
factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent our
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529897810/en/
press@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025